Flexid

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2024-01-31 05:02

Flexid: instructions for use and reviews

1. Release form and composition
2. Pharmacological properties
3. Indications for use
4. Contraindications
5. Method of application and dosage
6. Side effects
7. Overdose
8. Special instructions
9. Application during pregnancy and lactation
10. Use in childhood
11. In case of impaired renal function
12. For violations of liver function
13. Use in the elderly
14. Drug interactions
15. Analogs
16. Terms and conditions of storage
17. Terms of dispensing from pharmacies
18. Reviews
19. Price in pharmacies

Latin name: Flexid

ATX code: J01MA12

Active ingredient: levofloxacin (levofloxacin)

Producer: LEK dd (Slovenia), Pharmaceutical Works POLPHARMA (Poland)

Description and photo updated: 22.11.2018

Prices in pharmacies: from 241 rubles.

Buy

Flexid is a broad-spectrum antimicrobial bactericidal drug.

Release form and composition

Dosage forms of Flexid:

film-coated tablets: biconvex, octagonal, light orange-pink color, scored on one (500 mg) or two (250 mg) sides (5, 7 or 10 pcs. in a blister, in a cardboard box 1, 2, 3 or 5 blisters);
solution for infusion: transparent liquid, yellow with a green tint (50 or 100 ml in a disposable bag made of low density polyethylene with a hanging loop, in a cardboard box of 1, 5 or 20 bags).

1 tablet contains:

active substance: levofloxacin hemihydrate - 256.23 or 512.46 mg (equivalent to levofloxacin in an amount of 250 or 500 mg, respectively);
additional components: sodium carboxymethyl starch, lactose monohydrate, colloidal anhydrous silicon dioxide, povidone, glyceryl dibehenate, croscarmellose sodium, talc;
film shell: titanium dioxide, macrogol 6000, hyprolose, yellow iron oxide, hypromellose, red iron oxide, talc.

1 ml of solution contains:

active substance: levofloxacin hemihydrate - 5.12 mg (equivalent to 5 mg levofloxacin);
additional components: sodium hydroxide solution 0.1 M and hydrochloric acid solution 1 M, water for injection, sodium chloride.

Pharmacological properties

Pharmacodynamics

Levofloxacin, the active substance of Flexid, is a broad-spectrum antibacterial bactericidal agent belonging to the group of fluoroquinolones. The agent blocks DNA gyrase (topoisomerase IIA) and topoisomerase IV, interferes with DNA synthesis. Shows activity against most strains of microorganisms both in vitro and in vivo.

The following are summarized data on the activity of the active substance based on the results of clinical observations and in vitro studies.

Microorganisms sensitive to levofloxacin [minimal inhibitory concentration (MIC) equal to or less than 2 mg / l]:

gram negative aerobes: Enterobacter aerogenes, Eikenella corrodens, Enterobacter cloacae, Enterobacter agglomerans, Citrobacter freundii, Actinobacillus actinomycetemcomitans, Escherichia coli, Enterobacter spp., Acinetobacter spp., Acinetobacter spp., Acinetobacter influenza -sensitive / -resistant), Klebsiella oxytoca, Haemophilus parainfluenzae, Klebsiella pneumoniae, Helicobacter pylori, Klebsiella spp., Neisseria gonorrhoeae non.png" />
gram-positive aerobes: Corynebacterium striatum, Corynebacterium diphtheriae, Enterococcus spp., Listeria monocytogenes, Enterococcus faecalis, Staphylococcus coagulase-negative methi-S (I) (methicillin-susceptible / epidermal-moderately susceptible), Streptococcus agalactiae, Streptococci groups C and G, Staphylococcus spp. (CNS), Streptococcus pneumoniae peni I / S / R (penicillin-sensitive / moderately sensitive / resistant), Viridans streptococci peni-S / R, Streptococcus pyogenes;
anaerobic microorganisms: Bifidobacterium spp., Propionibacterium spp., Fusobacterium spp., Bacteroides fragilis, Peptostreptococcus, Veillonella spp., Clostridium perfringens;
other microorganisms: Legionella pneumophila, Chlamydia pneumoniae, Legionella spp., Bartonella spp., Chlamydia trachomatis, Chlamydia psittaci, Mycobacterium tuberculosis, Mycobacterium spp., Mycoplasma hominalasis. Mycobacterium leprae. Uppl. spp.

Moderately sensitive microorganisms (MIC corresponds to 4 mg / l):

gram-negative aerobes: Campylobacter jejuni / coli, Burkholderia cepacia;
gram-positive aerobes: Enterococcus faecium, Corynebacterium xerosis, Corynebacterium urealyticum, Staphylococcus haemolyticus methi-R, Staphylococcus epidermidis methi-R (methicillin-resistant);
anaerobic microorganisms: Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides vulgatus, Porphyromonas spp., Prevotella spp.

Microorganisms resistant to levofloxacin (MIC exceeds 8 mg / l):

gram-negative aerobes: Alcaligenes xylosoxidans;
gram-positive aerobes: Staphylococcus coagulase-negative methi-R, Staphylococcus aureus methi-R, Corynebacterium jeikeium;
anaerobic microorganisms: Bacteroides thetaiotaomicron;
other microorganisms: Mycobacterium avium.

Microorganisms that are causative agents of infections, in the treatment of which the effectiveness of the drug has been proven in clinical trials:

gram-negative aerobes: Haemophilus parainfluenzae, Citrobacter freundii, Haemophilus influenzae, Enterobacter cloacae, Klebsiella pneumoniae, Escherichia coli, Morganella morganii, Moraxella (Branhamella) catarrhalis, Pseudomonas aerugilis, Proteces marns;
gram-positive aerobes: Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus pneumoniae;
other microbes: Mycoplasma pneumoniae, Legionella pneumophila, Chlamydia pneumoniae.

Cross-resistance is noted between levofloxacin and other drugs of the fluoroquinolone group. Due to the peculiarities of its mechanism of action, as a rule, cross-resistance does not arise between antibiotics of other groups and levofloxacin.

Pharmacokinetics

After a 60-minute intravenous (IV) infusion of levofloxacin at a dose of 500 mg to healthy volunteers, the maximum plasma concentration of levofloxacin (C _max) averages 6.2 μg / ml. In the dose range from 50 to 1000 mg, the pharmacokinetics of the substance is linear. The steady-state concentration of levofloxacin in the blood (C _ss), when administered 1 or 2 times a day at a dose of 500 mg, is observed within 48 hours. After 10 days of drip IV injections of Flexid 1 time per day, 500 mg C _{max of the} active substance in the blood plasma is 6.4 ± 0.8 μg / l, and the minimum concentration [observed before the next infusion (C _min)] - 0.6 ± 0.2 μg / ml. On day 10, intravenous infusion of levofloxacin 2 times a day C_min corresponds to 2.3 ± 0.5 μg / ml, and C _max - 7.9 ± 1.1 μg / ml. The volume of distribution (V _d) of the agent is approximately 100 liters both after a single and after multiple infusion infusion, which indicates a good penetration of the drug into tissues and organs.

When taken orally, Flexid is rapidly and almost completely absorbed from the digestive tract, C _max in the blood is reached within 1–2 hours. Food intake has practically no effect on the absorption of the active substance. The bioavailability of the drug is almost 99-100%, the connection with plasma proteins is 30-40%. When using the drug orally at a dose of 500 mg 1 time per day, the accumulation of the active substance is practically not observed, when the same dose is taken 2 times a day, it is noted to an insignificant extent. C _{ss are} reached within 3 days.

After oral administration of Flexid 500 mg in the secretion of the bronchial epithelium and the mucous membrane of the bronchi, C _max are noted after about 1 hour and are 10.8 and 8.3 μg / ml, respectively. In lung tissue, C _{max is} reached after 4–6 hours and is about 11.3 μg / ml. Concentrations of levofloxacin in the lungs are higher than those in plasma. The substance penetrates into the cerebrospinal fluid poorly. The average concentration of the drug in the urine 8–12 hours after oral administration of single doses of 150, 300 or 500 mg is 44 mg / l, 91 mg / l or 200 mg / l, respectively.

When administered parenterally, levofloxacin penetrates well into the bronchial mucosa, epithelial lining fluid, and alveolar macrophages. After intravenous administration, Flexid is also well distributed in the lung tissue and alveolar fluid, the penetration coefficient is 2–5 and 1, respectively, compared to plasma concentrations in the blood. With infusion of Flexid 500 mg 1 or 2 times a day for 3 days in the alveolar fluid, the maximum concentration of the drug was observed 2-4 hours after administration and were equal to 4 and 6.7 μg / ml, respectively. Levofloxacin is characterized by good distribution in the prostate gland, as well as in the cortical and cancellous bone tissue in the distal and proximal femur. The penetration coefficient at the ratio of bone tissue / blood plasma is 0.1–3;the average concentration ratio of the prostate gland / blood plasma is 1.84. The levels of the substance in urine are several times higher than plasma levels.

Levofloxacin is metabolized to an extremely small extent with the formation of levofloxacin-N-oxide and desmethyl-levofloxacin. These metabolites make up less than 5% of the amount of the substance that is excreted through the kidneys. The half-life (T½) of levofloxacin is 6–8 hours. The drug is excreted mostly by the kidneys (over 85% of the administered dose).

There are no significant differences in the pharmacokinetics of levofloxacin when taken orally and intravenously. This indicates that both routes of administration of Flexid are interchangeable.

Indications for use

According to the instructions, Flexid is recommended for use for the treatment of infections caused by strains of microorganisms sensitive to levofloxacin:

urinary tract infections (complicated and uncomplicated, including pyelonephritis);
lower respiratory tract infections (community-acquired pneumonia; acute and chronic bronchitis - for pills);
chronic bacterial prostatitis;
infections of the skin and soft tissues;
ENT infections (acute sinusitis) - for pills;
pulmonary anthrax (prevention / treatment) - for solution;
drug-resistant forms of tuberculosis (as part of complex therapy).

Contraindications

Absolute:

pregnancy and the period of breastfeeding;
tendon lesions caused by previous fluoroquinolone therapy;
pseudoparalytic myasthenia gravis (myasthenia gravis) (due to the increased risk of neuromuscular blockade);
epilepsy;
impaired absorption of glucose / galactose, lactase deficiency, lactose intolerance - for tablets (since lactose is included in the composition);
age up to 18 years;
hypersensitivity to any of the constituents of the drug or other quinolones.

Relative (use Flexid with care):

myocardial infarction, heart failure, bradycardia and other heart diseases;
deficiency of glucose-6-phosphate dehydrogenase (due to an increased risk of hemolysis), renal failure, combined use with drugs that affect tubular secretion (including cimetidine, probenecid), diabetes mellitus;
the presence of risk factors for prolongation of the QT interval: congenital syndrome of a prolonged QT interval, combined use with drugs that can prolong the QT interval (tricyclic antidepressants, class IA and III antiarrhythmics, antipsychotics, macrolides; it should be borne in mind that elderly patients, as well as women, can be more susceptible to drugs that prolong the QT interval), uncorrected electrolyte disturbances (hyponatremia, hypokalemia, hypomagnesemia);
a history of psychoses and other mental disorders;
elderly age;
hepatic porphyria;
predisposition to convulsive reactions: organic diseases of the central nervous system, atherosclerosis of the vessels of the brain; a history of circulatory disorders of the brain (since Flexid can lower the threshold of convulsive readiness);
concomitant use of drugs that can lower the seizure threshold of the brain, such as fenbufen and other similar non-steroidal anti-inflammatory drugs (NSAIDs), theophylline.

Instructions for the use of Flexid: method and dosage

The dose of Flexid and the duration of therapy are determined taking into account the indications, nature and severity of the infection. Treatment with the drug must be continued for at least 48–72 hours after the symptoms of the lesion have subsided. The course of therapy cannot be prematurely terminated or suspended without a doctor's prescription.

Flexid tablets should be taken orally 1–2 times a day, swallowed without chewing, with plenty of liquid. Food intake does not reduce the effectiveness of the drug. If necessary, to facilitate the selection of the dose, the tablet can be broken into parts according to the separation risk. When taken orally, the maximum daily dose should not exceed 1000 mg.

The solution is required to be administered slowly by means of drip intravenous infusion 1 or 2 times a day. The duration of the infusion should be at least 30 minutes with the introduction of levofloxacin at a dose of 250 mg and 60 minutes with the introduction of 500 mg. The solution for infusion can be combined with sodium chloride solution 0.9%, glucose solution 5% or glucose solution in Ringer's solution 2.5%, as well as combined solutions intended for parenteral nutrition (carbohydrates, electrolytes and amino acids).

The Flexid solution must not be mixed with alkaline solutions or heparin!

After 2-4 days of intravenous infusion, when an improvement in the patient's condition is achieved, he can be transferred to oral administration of an antibacterial agent. Since the oral bioavailability of levofloxacin is 99-100%, no dose adjustment is required when switching the patient to the tablet form.

The recommended dosing regimen for patients with normal renal activity (CC more than 50 ml / min) for both forms of Flexid:

community-acquired pneumonia: 1 or 2 times a day, 500 mg, course - 7-14 days;
acute sinusitis (for tablets): once a day, 500 mg, course - 10-14 days;
period of exacerbation of chronic bronchitis (for tablets): once a day, 250-500 mg, course - 7-10 days;
complicated urinary tract infections (including pyelonephritis): for tablets - once a day, 250-500 mg, course - 7-14 days; for solution - 500 mg once a day, course - 7-14 days; in the treatment of pyelonephritis, the course of treatment is 7-10 days;
uncomplicated urinary tract infections: 250 mg once a day, course - 3 days;
chronic bacterial prostatitis: 500 mg once a day, course - 28 days;
infections of the skin and soft tissues: for tablets - 1–2 times a day, 250–500 mg, course –7–14 days; for solution - 1–2 times a day, 500 mg, course - 7–14 days;
drug-resistant forms of tuberculosis (as part of complex therapy): 1 or 2 times a day, 500 mg, course - up to 3 months;
pulmonary anthrax (prevention / treatment - for solution): once a day, 500 mg, course - no more than 8 weeks.

In the presence of impaired renal function (CC below 50 ml / min), individual dose selection is required.

The recommended dosing regimen for patients with functional impairment of the kidneys with CC below 50 ml / min, taking into account the severity of the infection (CC is measured in ml / min), for both forms of Flexid:

CC 50–20: I dose - 250 mg / 24 hours, the next - 125 mg / 24 hours; I dose - 500 mg for 12/24 hours, the next - 250 mg for 12/24 hours, respectively;
CC 19-10: I dose - 250 mg / 24 hours, the next - 125 mg / 48 hours; I dose - 500 mg for 12/24 hours, the next - 125 mg for 12/24 hours, respectively;
CC below 10 (including hemodialysis and CAPD) *: I dose - 250 mg / 24 hours, the next - 125 mg / 48 hours; I dose - 500 mg for 12/24 hours, the next - 125 mg / 24 hours.

* No additional doses are required after a hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) session.

Side effects

Gastrointestinal tract: often - vomiting, diarrhea, nausea; infrequently - dyspepsia, abdominal pain, constipation, flatulence; with an unknown frequency - pancreatitis, hepatitis, stomatitis, diarrhea mixed with blood (in rare cases, it may indicate the development of enterocolitis, including pseudomembranous colitis);
liver and biliary tract: often - increased activity of alkaline phosphatase (ALP), hepatic transaminases and gamma-glutamyltransferase (GGT); infrequently - an increase in the plasma concentration of bilirubin; with an unknown frequency - jaundice, hepatitis, severe liver failure, including acute liver failure, in some cases with a fatal outcome, mainly in patients with severe underlying disease (for example, with sepsis);
cardiovascular system: often - phlebitis (for Flexid solution); rarely - a decrease in blood pressure, sinus tachycardia, heart palpitations; with an unknown frequency - ventricular arrhythmias, prolongation of the QT interval, ventricular tachycardia of the "pirouette" type (in most cases, in the presence of risk factors for prolongation of the QT interval, which can lead to cardiac arrest);
nervous system: often - dizziness, insomnia, headache; infrequently - increased excitability, anxiety, anxiety, drowsiness, tremors, confusion; rarely - convulsions, paresthesias, nightmares, agitation, disorientation, depression, psychotic reactions (including paranoia, hallucinations); with an unknown frequency - benign intracranial hypertension, syncope, peripheral sensory neuropathy, dyskinesia, peripheral sensory-motor neuropathy, coordination disorders (including extrapyramidal disorders), suicidal thoughts / attempts, mental disorders, accompanied by behavioral disturbances with self-harm;
metabolism and nutritional disorders: infrequently - anorexia; rarely - hypoglycemia (increased sweating, increased appetite, tremors - mainly in patients with diabetes mellitus); extremely rarely - attacks of porphyria (porphyria is a rare metabolic pathology, attacks occur in patients already suffering from this disease, according to the experience of using other quinolones; the likelihood of this complication is also not excluded when using levofloxacin); with an unknown frequency - hyperglycemia, hypoglycemic coma;
sense organs: infrequently - vertigo, violation of taste sensitivity (dysgeusia); rarely - ringing in the ears, impaired visual perception; with an unknown frequency - hearing loss / loss, transient loss of vision, impairment / loss of smell, loss of taste sensitivity (ageusia);
urinary system: infrequently - hypercreatininemia; rarely - acute renal failure (including as a result of the development of interstitial nephritis);
musculoskeletal system: infrequently - myalgia, arthralgia; rarely - muscle weakness (especially important for patients with myasthenia gravis), tendonitis; with unknown frequency - tendon rupture (eg, Achilles tendon), muscle / ligament rupture, arthritis, rhabdomyolysis;
respiratory system: infrequently - shortness of breath; with an unknown frequency - allergic pneumonitis, bronchospasm;
immune system: rarely - hypersensitivity reactions, angioedema; with an unknown frequency - anaphylactic shock, anaphylactoid shock (sometimes after the first IV injection of Flexid);
skin and soft tissues: infrequently - skin rash, itching, hyperhidrosis, urticaria; with an unknown frequency - photosensitivity reactions, leukocytoclastic vasculitis, exudative erythema multiforme, toxic epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome;
blood and lymphatic system: infrequently - leukopenia, eosinophilia; rarely - thrombocytopenia, neutropenia; with an unknown frequency - pancytopenia, agranulocytosis, hemolytic anemia;
others: often - reactions at the injection site (pain, redness); infrequently - superinfection, fungal infections, asthenia; rarely - pyrexia (fever); with an unknown frequency - pain, including localized in the chest, back, limbs.

Overdose

Symptoms of an overdose of Flexid may include: erosion of the gastrointestinal mucous membranes, nausea, dizziness, tremors, convulsions, hallucinations, impairment / loss of consciousness, prolongation of the QT interval. In this condition, ECG parameters are monitored and symptomatic therapy is performed. Hemodialysis is ineffective, and the specific antidote is unknown.

special instructions

Flexid tablets should be taken at least 2 hours before or 2 hours after taking iron salts or antacids containing aluminum and / or magnesium, as well as sucralfate and didanosine (only those didanosine preparations in which the auxiliary substances are magnesium and aluminum). These funds cannot be taken simultaneously with levofloxacin, since they significantly reduce its absorption. If it is required to use sucralfate simultaneously with Flexid, the latter is recommended to be taken 2 hours after taking levofloxacin.

If a seizure develops during the period of therapy, the drug must be canceled immediately.

When taking levofloxacin in combination with indirect anticoagulants, which are coumarin derivatives, blood coagulation parameters should be monitored.

In rare cases, tendonitis that occurs during therapy with quinolones can cause rupture of the ligaments, mainly the Achilles tendon. This complication develops within 48 hours after the start of the course. In the elderly and patients taking glucocorticosteroids, the risk of tendinitis increases, therefore, such patients should be closely monitored while using levofloxacin. If you suspect the development of tendonitis, the use of Flexid should be discontinued and appropriate measures should be taken (for example, immobilization of the affected tendon).

Diarrhea (especially severe, persistent and / or bloody) on the background of drug treatment or after its completion can be a sign of a disease caused by Clostridium difficile, the most serious form of which is pseudomembranous colitis. If there is a suspicion of this complication, Flexid should be immediately canceled and symptomatic therapy should be carried out (including oral administration of vancomycin), drugs that suppress peristalsis are contraindicated in this case.

During the period of infusion of the solution, the appearance of such adverse reactions as tachycardia and a pronounced decrease in blood pressure is possible. If, with intravenous administration of Flexid, a significant decrease in blood pressure is noted, the infusion must be stopped immediately.

Patients on a diet with limited consumption of table salt should take into account that 100 ml of Flexid solution contains approximately 354 mg (15.4 mmol) of table salt.

During therapy and for at least 48 hours after its completion, exposure to direct sunlight and artificial ultraviolet radiation (solarium) should be avoided in order to prevent the occurrence of photosensitization reactions.

If during the course the development of symptoms of liver damage, which include darkening of urine, itching, jaundice, anorexia and abdominal pain, is observed, it is required to cancel the drug treatment and consult a doctor.

In patients with diabetes mellitus receiving treatment with insulin or oral hypoglycemic drugs (for example, glibenclamide), when using Flexid, the risk of hypo / hyperglycemia increases. As a result, patients with diabetes are advised to carefully monitor their plasma glucose levels.

While taking fluoroquinolones, cases of sensory and sensory-motor peripheral neuropathy have been reported, which may be characterized by a rapid onset of development. To prevent the occurrence of irreversible conditions, when symptoms of neuropathy appear, the use of levofloxacin should be urgently discontinued.

Treatment with levofloxacin, especially long-term, can provoke an increase in the growth of microorganisms insensitive to Flexid. When superinfection develops, appropriate measures must be taken.

Since levofloxacin is able to inhibit the growth of Mycobacterium tuberculosis, it is possible to obtain a false-negative result of bacteriological diagnosis of tuberculosis during therapy.

When an antibacterial agent is administered, urinalysis for opiates can give a false-positive result. In this case, it is recommended to use more specific methods.

Influence on the ability to drive vehicles and complex mechanisms

During the use of Flexid, the appearance of dizziness, confusion, visual impairment and other negative effects may occur, leading to a deterioration in concentration and speed of motor / mental reactions. As a result, patients receiving the drug need to take special care when driving vehicles and operating other complex equipment.

Application during pregnancy and lactation

In animal studies, the reproductive toxicity of the drug was not detected. Since there is no similar information on the use of the drug in humans, and also given the possibility of a negative effect of fluoroquinolone drugs on the cartilaginous points of growth of the skeleton (according to experimental data), the appointment of Flexid to pregnant women is contraindicated.

It is not known whether the drug penetrates into breast milk, therefore, if it is necessary to use levofloxacin during lactation, breastfeeding should be stopped.

Pediatric use

For patients under the age of 18, the use of Flexid is contraindicated due to the possible threat of damage to the articular cartilage.

With impaired renal function

Since levofloxacin is excreted mainly by the kidneys, kidney function monitoring is required in patients with renal insufficiency. In the presence of functional disorders of the kidneys with CC below 50 ml / min, the dose must be selected individually.

For violations of liver function

In case of violations of the liver, there is no need for a special selection of doses of Flexid, since levofloxacin is metabolized in the liver only to a small extent.

Use in the elderly

Elderly people do not need to change the dosage regimen of Flexid, however, CC should be monitored, since in patients of this age category, the risk of concomitant deterioration of renal function is aggravated.

Drug interactions

theophylline - no pharmacokinetic interaction was found, however, with the combined use of this agent with quinolones, the seizure threshold may be lowered;
fenbufen - the concentration of levofloxacin increases by about 13%;
cyclosporin - T½ of this drug increases by 33%;
probenecid and cimetidine - the renal clearance of levofloxacin decreases by 34% and 24%, respectively, as a result of blocking tubular secretion (these combinations require caution, especially in the presence of functional renal disorders);
glibenclamide, calcium carbonate, digoxin, ranitidine - no clinically significant effect on the pharmacokinetics of levofloxacin was recorded;
warfarin and other vitamin K antagonists - blood clotting parameters increase (prothrombin time) and / or the risk of bleeding increases.

Analogs

Flexid's analogs are: Levoximed, Lebel, Ivacin, Glevo, Levotek, Levolet R, Levostar, Levotek, Levoflox, Levofloxacin, Levofloxabol, Levofloxacin STADA, Levofloxacin-Nova, Levofloxacin-SOLOpharm, Levofloxacin, Leflobakin, Lefobaktin Lufy, MAKLEVO, OD-Levox, Oftaquix, Remedia, Roflox-Scan, Signicef, Tavanik, Tanflomed, Floracid, Haileflox, Ekolevid, Eleflox.

Terms and conditions of storage

Store in a place out of the reach of children, protected from light penetration, at a temperature not exceeding 25 ° C.

Shelf life of the drug - 3 years, ready-to-use solution for infusion - no more than 8 hours at a temperature of 22-25 ° C.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Flexid

Reviews of Flexid in tablet form are quite controversial. One group of patients characterizes Flexid as an effective agent successfully used for the treatment of many infectious diseases. The drug, according to their reviews, quickly lowers the temperature, relieves the symptoms of inflammation, improves the general condition, it is also easy to use and has a low cost.

Another group of patients considers the antibiotic effect insufficiently effective and indicates a large number of negative reactions that occurred during treatment (the most frequent are dizziness, insomnia, nausea, vomiting, pain in the stomach and liver, muscle weakness, heart palpitations), which in some cases became the reason for its cancellation.

There are no reviews of the solution for infusion.

Price for Flexid in pharmacies

The approximate price for Flexid film-coated tablets at a dosage of 500 mg is: 5 pcs. in the package - 240-350 rubles, 14 pcs. - 670-720 rubles. The reliable price of the solution for infusion is unknown, since at present this dosage form of the drug is not sold in pharmacies.

Flexid: prices in online pharmacies

Drug name

Price

Pharmacy

Flexid 500 mg film-coated tablets 5 pcs.

241 RUB

Buy

Flexid tablets p.p. 500mg 5 pcs.

253 r

Buy

Flexid 500 mg film-coated tablets 14 pcs.

RUB 670

Buy

Flexid tablets p.p. 500mg 14 pcs.

674 r

Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!